02:14 PM EDT, 04/09/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) was down 11% on last look, after the company on Tuesday after new preclinical data on MDNA113, its T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, was presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9.

According to a statement, MDNA113 is targeted to the tumor site where it is activated to deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer-fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicity. MDNA113 is the company's most advanced pre-clinical candidate.

Medicenna shares were last seen down C$0.18, or 11% to $1.52 on the Toronto Stock Exchange.

Price: 1.52, Change: -0.18, Percent Change: -10.59